Category: Clinical Trials

Study: An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies

This is a Phase 1/2 clinical research study for subjects with advanced malignancies. This study will be conducted in three treatment groups with each treatment having two parts; a dose escalation (Part 1) and an expansion (Part 2). This study is accepting patients with Diffuse Large B-Cell Lymphoma (DLBCL), Acute Myeloid Leukemia, Myelodysplastic /Myeloproliferative neoplasms… Read More

Posted by ALCF Staff on October 18th, 2016

Study: INCB039110 in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

This is a phase 1/2 clinical research study for patients with relapsed diffuse large B-cell lymphoma. The purpose of this study is to evaluate the safety and efficacy of INCB039110 when used in combination with Ibrutinib. To participate in this study, patients must have relapsed or refractory diffuse large B-cell lymphoma; have received 1-3 prior… Read More

Posted by ALCF Staff on October 18th, 2016

Study: A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and INCB039110 in Subjects With Previously Treated B-Cell Malignancies

This is a Phase 1/2 clinical research study in patients with previously treated B-cell malignancies. Examples of eligible B-cell malignancies include: Hodgkin’s lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma, and chronic lymphocytic leukemia. The primary purpose of this study is to study the safety and tolerability of INCB050465… Read More

Posted by ALCF Staff on October 18th, 2016

Study: A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers

This is a phase 1/2 immunotherapy combination clinical research study for patients who have been diagnosed with one of the following conditions: Diffuse Large B-Cell Lymphoma, Non-Small-Cell Lung Carcinoma, Transitional Cell Carcinoma of Genitourinary Tract (e.g., bladder), Triple Negative Breast Cancer, Squamous Cell Carcinoma of Head and Neck, Ovarian Cancer, Endometrial Cancer, and Renal Cell… Read More

Posted by ALCF Staff on October 18th, 2016

Study: A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers

This is a Phase 1/2 clinical research study that will be conducted in 2 parts (Phase 1 of the study has recently been completed and Phase 2 is currently ongoing). The primary purpose of this study is to evaluate safety, tolerability, and efficacy of two investigational drugs (Epacadostat and Nivolumab) when taken in combination for… Read More

Posted by ALCF Staff on October 18th, 2016

Liquid Biopsy Test Approved by the FDA for EGFR+ Lung Cancer

On June 1, 2016 the US Food and Drug Administration (FDA) approved the first ever blood test to aid clinical decision making for targeted therapies for lung cancer. This blood test, a companion diagnostic called Cobas EGFR Mutation Test v2, allows the detection of mutations in the EGFR (Epidermal Growth Factor Receptor) gene, such as… Read More

Posted by Dr. Guneet Walia on September 29th, 2016

Invictan-2 Clinical Trial for Nonsquamous NSCLC

A new clinical trial from Boehringer Ingelheim will be studying the safety and efficacy of a new drug call INVICTAN-2. The drug is similar to the biologic medication Avastin (bevacizumab) which is already approved as a treatment for nonsquamous non-small cell lung cancer. In order to be eligible to participate, you must meet the following… Read More

Posted by ALCF Staff on August 31st, 2016

Attention ROS-1 Positive Patients: Clinical Trial Opportunity

There is currently a clinical trial opportunity for patients with ROS1 fusion positive cancers. The STARTRK-2 trial, sponsored by Ignyta, is recruiting patients internationally who have DNA rearrangements affecting the NTRK, ROS1, or ALK genes. Your doctor can order a no-cost test to see if your cancer has one of these rearrangements. In most cases,… Read More

Posted by ALCF Staff on August 3rd, 2016

Lung Cancer Updates from ASCO 2016

Download PDF of this post What is ASCO? ASCO is the American Society of Clinical Oncology that has an annual meeting each year where key research and clinical medicine highlights are presented by cancer researchers & clinicians to the global community. This was the 52nd Annual Meeting of the American Society of Clinical Oncology, held… Read More

Posted by Dr. Guneet Walia on July 20th, 2016

New Clinical Trial Available for ALK+ NSCLC patients- XALT2

If you have non-small cell lung cancer (NSCLC), you may be interested in learning more about a clinical research study opportunity. Non-small cell lung cancer (NSCLC) is one of two types of lung cancer (the other is small cell lung cancer). Most lung cancers are NSCLC. Of the people who have NSCLC, only 3 percent… Read More

Posted by Danielle Hicks on April 1st, 2016